#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Familial dilated cardiomyopathy Cutaneous T-cell lymphoma stage I Albright's disease Pancreatic neuroendocrine tumour Parkinson's disease Erdheim-Chester disease Gastrooesophageal cancer HER2 gene amplification Isodicentric chromosome 15 syndrome Follicular lymphoma stage III Kaposi's sarcoma Macular telangiectasia Nephroblastoma Penile cancer Giant cell tumour of tendon sheath More trials…

    Learn about Rare Diseases

    Thrombotic thrombocytopenic purpura – Life with Disease Glycogen storage disease type II – Life with Disease Burkitt’s lymphoma – Diagnostics Cerebral arteriovenous malformation haemorrhagic – Life with Disease Mantle cell lymphoma stage III – Diagnostics Sjogren’s syndrome – Treatment Lennox-Gastaut syndrome – Basic Information Langerhans’ cell histiocytosis Angiosarcoma recurrent – Treatment Medulloblastoma recurrent – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Poa Pratensis Binimetinib Oxacillin Sodium Acetate (1-13C) Dosulepin Hydrochloride OMECAMTIV MECARBIL Efruxifermin Pp1815 Pegenzileukin Tetracycline Hydrochloride ISPAGHULA HUSK Basiliximab Tipranavir Acetazolamide Sodium Colecalciferol Dl-Alpha-Tocopherol Ketamine Xp-Dc+Tl+Klh Specific Nucleic Acid Sna-Her1 Gs-5245 More therapies…

    Learn about Your Condition

    Eclampsia Heparin resistance Epithelioid sarcoma Antithrombin III deficiency Cholangiosarcoma Fatty acid oxidation disorder Hodgkin's disease refractory Brain stem glioma Liver transplant rejection Malignant mast cell neoplasm High-grade B-cell lymphoma Hepatocellular carcinoma Behcet's syndrome Dengue fever Follicular thyroid cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Squamous cell carcinoma of head and neck

  • A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Nivolumab
    France

  • A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Rbl015.2
    • Rbl016.2
    • Pembrolizumab
    Austria Belgium Czechia France Germany Hungary +5

  • Study of nivolumab and ipilimumab immunotherapy for organ preservation in patients with advanced head and neck squamous cell carcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    The Netherlands

  • Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • LIGUFALIMAB
    • Ivonescimab
    • Pembrolizumab
    Belgium France Spain

  • A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Amivantamab
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Germany Hungary +6

  • Testing the Safety and Effects of TUB-030 in Patients with Advanced Head and Neck Cancer or Non-Small-Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • TUB-030
    France Romania Spain
1 2 3 … 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!